文献速递前列腺癌男科与性医学

BRCA1与BRCA2携带者前列腺癌筛查的社会心理影响

The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
PubMed 文献 · BJU Int · 2024-06-05

该研究为IMPACT研究的一部分,对BRCA1/BRCA2致病变异携带者及非携带对照每年筛查前完成心理社会问卷至少5年。整体未发现临床关注的痛苦或健康相关生活质量下降,对照对前列腺癌担忧显著低于携带者但均分低,BRCA2携带者既往PSA高者前列腺癌焦虑与PSA特异性焦虑小幅但显著增加。

要点

  • 每年PSA筛查未对BRCA1/BRCA2携带者心理社会健康或健康相关生活质量产生不良影响。
  • 对照组对前列腺癌的担忧显著低于携带者,但所有均分均低且多在一般人群常模内。
  • BRCA2携带者中既往PSA水平高者前列腺癌焦虑(P=0.01)与PSA特异性焦虑(P<0.001)小幅但显著增加。

核心结论

  • 每年一次基于PSA的筛查方案未对这些较高风险个体的心理社会健康或健康相关生活质量产生不良影响。
  • 随着更多前列腺癌筛查针对较高风险群体,这些结果具有重要意义。

研究设计与样本

  • IMPACT研究是一项多国靶向前列腺癌筛查研究,纳入BRCA1或BRCA2种系致病变异携带者及对照。
  • 参与者每年筛查访视前完成心理社会问卷,至少5年。
  • 共760名参与者完成问卷:BRCA1致病变异207人、BRCA2致病变异265人、对照288人(来自已知致病变异家庭的非携带者)。

主要发现

  • 整体队列未发现临床关注水平的一般或癌症特异性痛苦或健康相关生活质量差。
  • 对照组对前列腺癌的担忧显著低于携带者,但所有均分均低且在可获得的一般人群常模内。
  • BRCA2携带者中既往PSA水平高者前列腺癌焦虑小幅但显著增加(P=0.01),PSA特异性焦虑小幅但显著增加(P<0.001)。
  • 癌症风险感知反映了遗传咨询提供的信息,参与者知识水平良好,但随时间下降。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To report the long-term outcomes from a longitudinal psychosocial study that forms part of the 'Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls' (IMPACT) study. The IMPACT study is a multi-national study of targeted prostate cancer (PrCa) screening in individuals with a known germline pathogenic variant (GPV) in either the BReast CAncer gene 1 (BRCA1) or the BReast CAncer gene 2 (BRCA2). SUBJECTS AND METHODS: Participants enrolled in the IMPACT study were invited to complete a psychosocial questionnaire prior to each annual screening visit for a minimum of 5 years. The questionnaire included questions on sociodemographics and the following measures: Hospital Anxiety and Depression Scale, Impact of Event Scale, 36-item Short-Form Health Survey, Memorial Anxiety Scale for PrCa, Cancer Worry Scale, risk perception and knowledge. RESULTS: A total of 760 participants completed questionnaires: 207 participants with GPV in BRCA1, 265 with GPV in BRCA2 and 288 controls (non-carriers from families with a known GPV). We found no evidence of clinically concerning levels of general or cancer-specific distress or poor health-related quality of life in the cohort as a whole. Individuals in the control group had significantly less worry about PrCa compared with the carriers; however, all mean scores were low and within reported general population norms, where available. BRCA2 carriers with previously high prostate-specific antigen (PSA) levels experience a small but significant increase in PrCa anxiety (P = 0.01) and PSA-specific anxiety (P < 0.001). Cancer risk perceptions reflected information provided during genetic counselling and participants had good levels of knowledge, although this declined over time. CONCLUSION: This is the first study to report the longitudinal psychosocial impact of a targeted PrCa screening programme for BRCA1 and BRCA2 carriers. The results reassure that an annual PSA-based screening programme does not have an adverse impact on psychosocial health or health-related quality of life in these higher-risk individuals. These results are important as more PrCa screening is targeted to higher-risk groups.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Bancroft EK, Page EC, Brook MN, et al. The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers. BJU Int. 2024. PMID: 38839570. doi:10.1111/bju.16432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。